Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche/DuPont

Executive Summary

Parkinson's disease therapies Tasmar (tolcapone) and Sinemet CR (sustained-release carbidopa-levodopa) will be co-promoted for three years in the U.S. Roche's Tasmar, approved Jan. 29, is indicated for use as an adjunct to carbidopa and levodopa therapy. Over 500 Roche reps and a "few hundred" DuPont reps will promote the compounds. The co-promotion agreement provides additional support to DuPont's second top-selling Rx product line as the company forges an independent presence after the dissolution of the DuPont Merck joint venture. DuPont says the agreement with Roche will not affect the profit equalization formula of its license of the antihypertensives Cozaar/Hyzaar to Merck: the formula takes into account sales of the Sinemet line as well as Cozaar/Hyzaar sales and spending
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS032647

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel